Quarterly Result30 May 2025, 09:52 pm
AstraZeneca Pharma India Limited Marks a Consistent 32% Growth, Announcing Annual Results for FY 2024-25
AI Summary
AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, announced its full-year performance for the financial year April 2024-March 2025. The company achieved a significant 32% increase in revenue compared to the same period last year, driven by strong growth across therapeutic areas. The total revenue from operations stands at INR 17162.9 Mn. Key product approvals and launches include Palivizumab, Tremelimumab, Durvalumab, Olaparib + Durvalumab, Budesonide/Glycopyrronium/Formoterol, Eculizumab, and Sodium Zirconium Cyclosilicate. AstraZeneca Pharma India Limited is committed to delivering sustainable value to people, society, and the planet.
Key Highlights
- AstraZeneca Pharma India Limited records a 32% increase in revenue compared to the same period last year.
- Total revenue from operations stands at INR 17162.9 Mn.
- Key product approvals and launches include Palivizumab, Tremelimumab, Durvalumab, Olaparib + Durvalumab, Budesonide/Glycopyrronium/Formoterol, Eculizumab, and Sodium Zirconium Cyclosilicate.
- AstraZeneca Pharma India Limited is committed to delivering sustainable value to people, society, and the planet.